Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients

December 3, 2015 4:37 PM EST Send to a Friend
A retrospective analysis of Novocure’s (Nasdaq: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login